Publicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Salamanca (8)

2024

  1. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer

    Cancer Medicine, Vol. 13, Núm. 17

2023

  1. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

2020

  1. Stromal SNAI2 is required for ERBB2 breast cancer progression

    Cancer Research, Vol. 80, Núm. 23, pp. 5216-5230

2019

  1. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  2. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin

    Frontiers in Oncology, Vol. 9, Núm. MAR

2018

  1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

2015

  1. Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach

    Genome Biology, Vol. 16, Núm. 1